248 related articles for article (PubMed ID: 35676421)
21. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
22. Identification of the Key miRNAs and Genes Associated with the Regulation of Non-Small Cell Lung Cancer: A Network-Based Approach.
Shafat Z; Ahmed MM; Almajhdi FN; Hussain T; Parveen S; Ahmed A
Genes (Basel); 2022 Jun; 13(7):. PubMed ID: 35885958
[TBL] [Abstract][Full Text] [Related]
23. Analysis of gene expression profiles of non-small cell lung cancer at different stages reveals significantly altered biological functions and candidate genes.
Wang J; Song J; Gao Z; Huo X; Zhang Y; Wang W; Qi J; Zheng S
Oncol Rep; 2017 Mar; 37(3):1736-1746. PubMed ID: 28098899
[TBL] [Abstract][Full Text] [Related]
24. Considering smoking status, coexpression network analysis of non-small cell lung cancer at different cancer stages, exhibits important genes and pathways.
Mortezaei Z; Tavallaei M; Hosseini SM
J Cell Biochem; 2019 Nov; 120(11):19172-19185. PubMed ID: 31271232
[TBL] [Abstract][Full Text] [Related]
25. Identification of lung-cancer-related genes with the shortest path approach in a protein-protein interaction network.
Li BQ; You J; Chen L; Zhang J; Zhang N; Li HP; Huang T; Kong XY; Cai YD
Biomed Res Int; 2013; 2013():267375. PubMed ID: 23762832
[TBL] [Abstract][Full Text] [Related]
26. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
[TBL] [Abstract][Full Text] [Related]
27. Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinoma.
Graves OK; Kim W; Özcan M; Ashraf S; Turkez H; Yuan M; Zhang C; Mardinoglu A; Li X
Biomed Pharmacother; 2023 May; 161():114486. PubMed ID: 36906970
[TBL] [Abstract][Full Text] [Related]
28. Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis.
Piao J; Sun J; Yang Y; Jin T; Chen L; Lin Z
Gene; 2018 Mar; 647():306-311. PubMed ID: 29305979
[TBL] [Abstract][Full Text] [Related]
29. A novel framework for inferring condition-specific TF and miRNA co-regulation of protein-protein interactions.
Zhang J; Le TD; Liu L; He J; Li J
Gene; 2016 Feb; 577(1):55-64. PubMed ID: 26611531
[TBL] [Abstract][Full Text] [Related]
30. Identification of the shared gene signatures and molecular mechanisms between multiple sclerosis and non-small cell lung cancer.
Yang J; Hu X; Wang Y; Liu W; Zhang M; Zhang A; Ni B
Front Immunol; 2023; 14():1180449. PubMed ID: 37251402
[TBL] [Abstract][Full Text] [Related]
31. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.
Tan X; Chen M
Tumour Biol; 2014 Dec; 35(12):12189-200. PubMed ID: 25179839
[TBL] [Abstract][Full Text] [Related]
32. Identification of potential therapeutic target genes and mechanisms in non-small-cell lung carcinoma in non-smoking women based on bioinformatics analysis.
Zhou W; Yin M; Cui H; Wang N; Zhao LL; Yuan LZ; Yang XP; Ding XM; Men FZ; Ma X; Na JR
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3375-84. PubMed ID: 26439031
[TBL] [Abstract][Full Text] [Related]
33. Current standards of care in small-cell and non-small-cell lung cancer.
Schiller JH
Oncology; 2001; 61 Suppl 1():3-13. PubMed ID: 11598409
[TBL] [Abstract][Full Text] [Related]
34. An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance.
Sun X; Yi J; Yang J; Han Y; Qian X; Liu Y; Li J; Lu B; Zhang J; Pan X; Liu Y; Liang M; Chen E; Liu P; Lu Y
Theranostics; 2021; 11(11):5346-5364. PubMed ID: 33859751
[No Abstract] [Full Text] [Related]
35. Functional analysis of microRNA and transcription factor synergistic regulatory network based on identifying regulatory motifs in non-small cell lung cancer.
Li K; Li Z; Zhao N; Xu Y; Liu Y; Zhou Y; Shang D; Qiu F; Zhang R; Chang Z; Xu Y
BMC Syst Biol; 2013 Nov; 7():122. PubMed ID: 24200043
[TBL] [Abstract][Full Text] [Related]
36. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
[TBL] [Abstract][Full Text] [Related]
37. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.
Tsai CM; Chang KT; Perng RP; Mitsudomi T; Chen MH; Kadoyama C; Gazdar AF
J Natl Cancer Inst; 1993 Jun; 85(11):897-901. PubMed ID: 8098377
[TBL] [Abstract][Full Text] [Related]
38. Network-based drug repurposing for schizophrenia.
Truong TTT; Liu ZSJ; Panizzutti B; Kim JH; Dean OM; Berk M; Walder K
Neuropsychopharmacology; 2024 May; 49(6):983-992. PubMed ID: 38321095
[TBL] [Abstract][Full Text] [Related]
39. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery.
Jia Z; Liu Y; Guan N; Bo X; Luo Z; Barnes MR
BMC Genomics; 2016 May; 17():414. PubMed ID: 27234029
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
